Open AccessSalmonella vaccines for use in humans: present and future perspectives
Author(s) -
Garmory Helen S,
Brown Katherine A,
Titball Richard W
Publication year - 2002
Publication title -
fems microbiology reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.91
H-Index - 212
eISSN - 1574-6976
pISSN - 0168-6445
DOI - 10.1111/j.1574-6976.2002.tb00619.x
Subject(s) - salmonella typhi , typhoid fever , salmonella enterica , microbiology and biotechnology , salmonella , biology , virology , antigen , heterologous , serotype , immunity , vaccination , immunology , bacteria , immune system , escherichia coli , gene , genetics
In recent years there has been significant progress in the development of attenuated Salmonella enterica serovar Typhi strains as candidate typhoid fever vaccines. In clinical trials these vaccines have been shown to be well tolerated and immunogenic. For example, the attenuated S. enterica var. Typhi strains CVD 908‐ htrA ( aroC aroD htrA ), Ty800 ( phoP phoQ ) and χ4073 ( cya crp cdt ) are all promising candidate typhoid vaccines. In addition, clinical trials have demonstrated that S. enterica var. Typhi vaccines expressing heterologous antigens, such as the tetanus toxin fragment C, can induce immunity to the expressed antigens in human volunteers. In many cases, the problems associated with expression of antigens in Salmonella have been successfully addressed and the future of Salmonella vaccine development is very promising.